• Deutsch
  • Home
  • Search
  • Browse
  • Publish
  • Help
Schließen
  • Faculties
  • Medizinische Fakultät

Institut für Experimentelle Biomedizin

Refine

Has Fulltext

  • yes (54)

Is part of the Bibliography

  • yes (54)

Year of publication

  • 2022 (3)
  • 2021 (13)
  • 2020 (10)
  • 2019 (7)
  • 2018 (2)
  • 2017 (4)
  • 2016 (11)
  • 2015 (2)
  • 2014 (1)
  • 2013 (1)
+ more

Document Type

  • Journal article (41)
  • Doctoral Thesis (13)

Language

  • English (50)
  • German (4)

Keywords

  • atherosclerosis (6)
  • ischemic stroke (5)
  • platelet (5)
  • platelets (5)
  • LASP1 (4)
  • megakaryocytes (4)
  • Thrombozyt (3)
  • mouse (3)
  • thrombo-inflammation (3)
  • AAA (2)
+ more

Author

  • Nieswandt, Bernhard (17)
  • Schulze, Harald (12)
  • Zernecke, Alma (12)
  • Stegner, David (9)
  • Butt, Elke (6)
  • Schuhmann, Michael K. (6)
  • Stoll, Guido (6)
  • Braun, Attila (4)
  • Heinze, Katrin G. (4)
  • Manukjan, Georgi (4)
+ more

Institute

  • Institut für Experimentelle Biomedizin (54)
  • Rudolf-Virchow-Zentrum (19)
  • Graduate School of Life Sciences (6)
  • Neurologische Klinik und Poliklinik (6)
  • Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (5)
  • Theodor-Boveri-Institut für Biowissenschaften (5)
  • Medizinische Klinik und Poliklinik I (4)
  • Physikalisches Institut (3)
  • Medizinische Klinik und Poliklinik II (2)
  • Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
+ more

Sonstige beteiligte Institutionen

  • Bio-Imaging Center Würzburg (1)
  • Fraunhofer Institute Interfacial Engineering and Biotechnology (IGB) (1)
  • Institute for Biochemistry I, University of Cologne (1)

EU-Project number / Contract (GA) number

  • 249929 (1)
  • 602300 (1)
  • 641833 (1)

54 search hits

  • 1 to 10
  • BibTeX
  • CSV
  • RIS
  • XML
  • 10
  • 20
  • 50
  • 100

Sort by

  • Year
  • Year
  • Title
  • Title
  • Author
  • Author
Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets (2022)
Rosa, Annabelle ; Butt, Elke ; Hopper, Christopher P. ; Loroch, Stefan ; Bender, Markus ; Schulze, Harald ; Sickmann, Albert ; Vorlova, Sandra ; Seizer, Peter ; Heinzmann, David ; Zernecke, Alma
Cyclophilin A (CyPA) is widely expressed by all prokaryotic and eukaryotic cells. Upon activation, CyPA can be released into the extracellular space to engage in a variety of functions, such as interaction with the CD147 receptor, that contribute to the pathogenesis of cardiovascular diseases. CyPA was recently found to undergo acetylation at K82 and K125, two lysine residues conserved in most species, and these modifications are required for secretion of CyPA in response to cell activation in vascular smooth muscle cells. Herein we addressed whether acetylation at these sites is also required for the release of CyPA from platelets based on the potential for local delivery of CyPA that may exacerbate cardiovascular disease events. Western blot analyses confirmed the presence of CyPA in human and mouse platelets. Thrombin stimulation resulted in CyPA release from platelets; however, no acetylation was observed—neither in cell lysates nor in supernatants of both untreated and activated platelets, nor after immunoprecipitation of CyPA from platelets. Shotgun proteomics detected two CyPA peptide precursors in the recombinant protein, acetylated at K28, but again, no acetylation was found in CyPA derived from resting or stimulated platelets. Our findings suggest that acetylation of CyPA is not a major protein modification in platelets and that CyPA acetylation is not required for its secretion from platelets.
Die Entwicklung und Charakterisierung Dendritischer Zell-Subsets in der gesunden und arteriosklerotischen Aorta (2022)
Westhofen, Thilo Chou-Jong
Arteriosklerose ist eine chronisch inflammatorische Erkrankung der Gefäßwand. Nach aktuellem Wissensstand sind Dendritische Zellen (DCs) maßgeblich an der Entstehung und dem Fortschreiten von Arteriosklerose beteiligt. In der Vergangenheit konnten für DCs unterschiedliche Subsets beschreiben werden, die sowohl proinflammatorische als auch immunregulatorische Funktionen übernehmen können. Die systematische Charakterisierung von DCs in der gesunden Aorta, sowie während der Entstehung von Arteriosklerose ist jedoch noch ausstehend. In der vorliegenden Arbeit wurde zunächst die systematische Einteilung von DCs in vitro mit Hilfe von DCs aus Flt3L-Knochenmarkskulturen durchgeführt. Aufbauend darauf erfolgte die systematische Analyse aortaler DCs durch tierexperimentelle Untersuchungen an gesunden C57BL/6J Mäusen, sowie Apolipoprotein E-defizienten (ApoE-/-) Mäusen und low-density-lipoprotein-receptor-defizienten (Ldlr-/-) Mäusen während der Atherogenese. Mittels immunhistochemischer Untersuchungen von CD11cYFPreporter Mäusen konnten zudem korrelierend DCs in der Gefäßwand der murinen Aorta lokalisiert werden. Zusammenfassend gibt die vorliegende Arbeit erstmalig einen systematischen Überblick über die einzelnen DC-Subsets in der gesunden Aorta und während der Atherogenese. Dies trägt zu einem besseren Verständnis der Rolle der einzelnen DC Subsets während der Entstehung der Arteriosklerose bei und bietet eine mögliche Grundlage für zukünftige Behandlungsstrategien. Die Ergebnisse dieser Arbeit wurden im Februar 2014 als Originalarbeit in geteilter Erstautorenschaft von Martin Busch, Thilo Westhofen und Miriam Koch unter dem Titel Dendritic Cell Subset Distributions in the Aorta in Healthy and Atherosclerotic Mice im Plos One publiziert (1). Die Originalpublikation findet sich im Folgenden unter Absatz 11. Die Ergebnisse dieser Publikation wurden modifiziert unter 6.1-6.5 dargelegt und unter 7.1-7.5 im Kontext der aktuellen Literatur diskutiert. Sofern nicht anders angegeben, wurden alle Experimente von Thilo Westhofen geplant, durchgeführt und ausgewertet.
Regulation of ion conductance and cAMP/cGMP concentration in megakaryocytes by light (2022)
Kurz, Hendrikje
Platelets play an essential role in haemostasis. Through granule secretion of second wave mediators and aggregation, they secure vascular integrity. Due to incorrect activation, platelet aggregation and subsequent thrombus formation can cause blood vessel occlusion, leading to ischemia. Patients with defects in platelet production have a low platelet count (thrombocytopenia), which can cause an increased bleeding risk. In vitro platelet generation is still in its development phase. So far, no convincing results have been obtained. For this reason, the health care system still depends on blood donors. Platelets are produced by bone marrow megakaryocytes (MKs), which extend long cytoplasmic protrusions, designated proplatelets, into sinusoidal blood vessels. Due to shear forces, platelets are then released into the bloodstream. The molecular mechanisms underlying platelet production are still not fully understood. However, a more detailed insight of this biological process is necessary to improve the in vitro generation of platelets and to optimise treatment regimens of patients. Optogenetics is defined as “light-modulation of cellular activity or of animal behaviour by gene transfer of photo-sensitive proteins”. Optogenetics has had a big impact on neuroscience over the last decade. The use of channelrhodopsin 2 (ChR2), a light-sensitive cation channel, made it possible to stimulate neurons precisely and minimally invasive for the first time. Recent developments in the field of optogenetics intend to address a broader scope of cellular and molecular biology. The aim of this thesis is to establish optogenetics in the field of MK research in order to precisely control and manipulate MK differentiation. An existing “optogenetic toolbox“ was used, which made it possible to light-modulate the cellular concentration of specific signalling molecules and ion conductance in MKs. Expression of the bacterial photoactivated adenylyl cyclase (bPAC) resulted in a significant increase in cAMP concentration after 5 minutes of illumination. Similarly, intracellular cGMP concentrations in MKs expressing photoactivated guanylyl cyclase (BeCyclop) were elevated. Furthermore, proplatelet formation of MKs expressing the light-sensitive ion channels ChR2 and anion channelrhodopsin (ACR) was altered in a light-dependent manner. These results show that MK physiology can be modified by optogenetic approaches. This might help shed new light on the underlying mechanisms of thrombopoiesis.
Effects of cocoa genotypes on coat color, platelets and coagulation parameters in French Bulldogs (2021)
Laukner, Anna ; Truchet, Laura ; Manukjan, Georgi ; Schulze, Harald ; Langbein-Detsch, Ines ; Mueller, Elisabeth ; Leeb, Tosso ; Kehl, Alexandra
A nonsense variant in HPS3, c.2420G>A or p.Trp807*, was recently discovered as the cause for a brown coat color termed cocoa in French Bulldogs. Here, we studied the genotype–phenotype correlation regarding coat color in HPS3 mutant dogs that carried various combinations of mutant alleles at other coat color genes. Different combinations of HPS3, MLPH and TYRP1 genotypes resulted in subtly different shades of brown coat colors. As HPS3 variants in humans cause the Hermansky–Pudlak syndrome type 3, which in addition to oculocutaneous albinism is characterized by a storage pool deficiency leading to bleeding tendency, we also investigated the phenotypic consequences of the HPS3 variant in French Bulldogs on hematological parameters. HPS3 mutant dogs had a significantly lowered platelet dense granules abundance. However, no increased bleeding tendencies in daily routine were reported by dog owners. We therefore conclude that in dogs, the phenotypic effect of the HPS3 variant is largely restricted to pigmentation. While an effect on platelet morphology is evident, we did not obtain any indications for major health problems associated with the cocoa coat color in French Bulldogs. Further studies will be necessary to definitely rule out very subtle effects on visual acuity or a clinically relevant bleeding disorder.
CD8\(^+\) T cells in atherosclerosis (2020)
Schäfer, Sarah ; Zernecke, Alma
Atherosclerotic lesions are populated by cells of the innate and adaptive immune system, including CD8\(^+\) T cells. The CD8\(^+\) T cell infiltrate has recently been characterized in mouse and human atherosclerosis and revealed activated, cytotoxic, and possibly dysfunctional and exhausted cell phenotypes. In mouse models of atherosclerosis, antibody-mediated depletion of CD8\(^+\) T cells ameliorates atherosclerosis. CD8\(^+\) T cells control monopoiesis and macrophage accumulation in early atherosclerosis. In addition, CD8\(^+\) T cells exert cytotoxic functions in atherosclerotic plaques and contribute to macrophage cell death and necrotic core formation. CD8\(^+\) T cell activation may be antigen-specific, and epitopes of atherosclerosis-relevant antigens may be targets of CD8\(^+\) T cells and their cytotoxic activity. CD8\(^+\) T cell functions are tightly controlled by costimulatory and coinhibitory immune checkpoints. Subsets of regulatory CD25\(^+\)CD8\(^+\) T cells with immunosuppressive functions can inhibit atherosclerosis. Importantly, local cytotoxic CD8\(^+\) T cell responses may trigger endothelial damage and plaque erosion in acute coronary syndromes. Understanding the complex role of CD8\(^+\) T cells in atherosclerosis may pave the way for defining novel treatment approaches in atherosclerosis. In this review article, we discuss these aspects, highlighting the emerging and critical role of CD8\(^+\) T cells in atherosclerosis.
Phosphorylation-dependent differences in CXCR4-LASP1-AKT1 interaction between breast cancer and chronic myeloid leukemia (2020)
Butt, Elke ; Stempfle, Katrin ; Lister, Lorenz ; Wolf, Felix ; Kraft, Marcella ; Herrmann, Andreas B. ; Viciano, Cristina Perpina ; Weber, Christian ; Hochhaus, Andreas ; Ernst, Thomas ; Hoffmann, Carsten ; Zernecke, Alma ; Frietsch, Jochen J.
The serine/threonine protein kinase AKT1 is a downstream target of the chemokine receptor 4 (CXCR4), and both proteins play a central role in the modulation of diverse cellular processes, including proliferation and cell survival. While in chronic myeloid leukemia (CML) the CXCR4 is downregulated, thereby promoting the mobilization of progenitor cells into blood, the receptor is highly expressed in breast cancer cells, favoring the migratory capacity of these cells. Recently, the LIM and SH3 domain protein 1 (LASP1) has been described as a novel CXCR4 binding partner and as a promoter of the PI3K/AKT pathway. In this study, we uncovered a direct binding of LASP1, phosphorylated at S146, to both CXCR4 and AKT1, as shown by immunoprecipitation assays, pull-down experiments, and immunohistochemistry data. In contrast, phosphorylation of LASP1 at Y171 abrogated these interactions, suggesting that both LASP1 phospho-forms interact. Finally, findings demonstrating different phosphorylation patterns of LASP1 in breast cancer and chronic myeloid leukemia may have implications for CXCR4 function and tyrosine kinase inhibitor treatment.
Infarct growth precedes cerebral thrombosis following experimental stroke in mice (2021)
Göb, Vanessa ; Voll, Maximilian G. ; Zimmermann, Lena ; Hemmen, Katharina ; Stoll, Guido ; Nieswandt, Bernhard ; Schuhmann, Michael K. ; Heinze, Katrin G. ; Stegner, David
Ischemic stroke is among the leading causes of disability and death worldwide. In acute ischemic stroke, successful recanalization of occluded vessels is the primary therapeutic aim, but even if it is achieved, not all patients benefit. Although blockade of platelet aggregation did not prevent infarct progression, cerebral thrombosis as cause of secondary infarct growth has remained a matter of debate. As cerebral thrombi are frequently observed after experimental stroke, a thrombus-induced impairment of the brain microcirculation is considered to contribute to tissue damage. Here, we combine the model of transient middle cerebral artery occlusion (tMCAO) with light sheet fluorescence microscopy and immunohistochemistry of brain slices to investigate the kinetics of thrombus formation and infarct progression. Our data reveal that tissue damage already peaks after 8 h of reperfusion following 60 min MCAO, while cerebral thrombi are only observed at later time points. Thus, cerebral thrombosis is not causative for secondary infarct growth during ischemic stroke.
Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents (2021)
Beck, Sarah ; Stegner, David ; Loroch, Stefan ; Baig, Ayesha A. ; Göb, Vanessa ; Schumbutzki, Cornelia ; Eilers, Eva ; Sickmann, Albert ; May, Frauke ; Nolte, Marc W. ; Panousis, Con ; Nieswandt, Bernhard
Background Effective inhibition of thrombosis without generating bleeding risks is a major challenge in medicine. Accumulating evidence suggests that this can be achieved by inhibition of coagulation factor XII (FXII), as either its knock-out or inhibition in animal models efficiently reduced thrombosis without affecting normal hemostasis. Based on these findings, highly specific inhibitors for human FXII(a) are under development. However, currently, in vivo studies on their efficacy and safety are impeded by the lack of an optimized animal model expressing the specific target, that is, human FXII. Objective The primary objective of this study is to develop and functionally characterize a humanized FXII mouse model. Methods A humanized FXII mouse model was generated by replacing the murine with the human F12 gene (genetic knock-in) and tested it in in vitro coagulation assays and in in vivo thrombosis models. Results These hF12\(^{KI}\) mice were indistinguishable from wild-type mice in all tested assays of coagulation and platelet function in vitro and in vivo, except for reduced expression levels of hFXII compared to human plasma. Targeting FXII by the anti-human FXIIa antibody 3F7 increased activated partial thromboplastin time dose-dependently and protected hF12\(^{KI}\) mice in an arterial thrombosis model without affecting bleeding times. Conclusion These data establish the newly generated hF12\(^{KI}\) mouse as a powerful and unique model system for in vivo studies on anti-FXII(a) biologics, supporting the development of efficient and safe human FXII(a) inhibitors.
Point of care diagnostic of hypercoagulability and platelet function in COVID-19 induced acute respiratory distress syndrome: a retrospective observational study (2021)
Herrmann, Johannes ; Notz, Quirin ; Schlesinger, Tobias ; Stumpner, Jan ; Kredel, Markus ; Sitter, Magdalena ; Schmid, Benedikt ; Kranke, Peter ; Schulze, Harald ; Meybohm, Patrick ; Lotz, Christopher
Background Coronavirus disease 2019 (COVID-19) associated coagulopathy (CAC) leads to thromboembolic events in a high number of critically ill COVID-19 patients. However, specific diagnostic or therapeutic algorithms for CAC have not been established. In the current study, we analyzed coagulation abnormalities with point-of-care testing (POCT) and their relation to hemostatic complications in patients suffering from COVID-19 induced Acute Respiratory Distress Syndrome (ARDS). Our hypothesis was that specific diagnostic patterns can be identified in patients with COVID-19 induced ARDS at risk of thromboembolic complications utilizing POCT. Methods This is a single-center, retrospective observational study. Longitudinal data from 247 rotational thromboelastometries (Rotem®) and 165 impedance aggregometries (Multiplate®) were analysed in 18 patients consecutively admitted to the ICU with a COVID-19 induced ARDS between March 12th to June 30th, 2020. Results Median age was 61 years (IQR: 51–69). Median PaO2/FiO2 on admission was 122 mmHg (IQR: 87–189), indicating moderate to severe ARDS. Any form of hemostatic complication occurred in 78 % of the patients with deep vein/arm thrombosis in 39 %, pulmonary embolism in 22 %, and major bleeding in 17 %. In Rotem® elevated A10 and maximum clot firmness (MCF) indicated higher clot strength. The delta between EXTEM A10 minus FIBTEM A10 (ΔA10) > 30 mm, depicting the sole platelet-part of clot firmness, was associated with a higher risk of thromboembolic events (OD: 3.7; 95 %CI 1.3–10.3; p = 0.02). Multiplate® aggregometry showed hypoactive platelet function. There was no correlation between single Rotem® and Multiplate® parameters at intensive care unit (ICU) admission and thromboembolic or bleeding complications. Conclusions Rotem® and Multiplate® results indicate hypercoagulability and hypoactive platelet dysfunction in COVID-19 induced ARDS but were all in all poorly related to hemostatic complications..
Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice (2021)
Schuhmann, Michael K. ; Bieber, Michael ; Franke, Maximilian ; Kollikowski, Alexander M. ; Stegner, David ; Heinze, Katrin G. ; Nieswandt, Bernhard ; Pham, Mirko ; Stoll, Guido
Background In acute ischemic stroke, cessation of blood flow causes immediate tissue necrosis within the center of the ischemic brain region accompanied by functional failure in the surrounding brain tissue designated the penumbra. The penumbra can be salvaged by timely thrombolysis/thrombectomy, the only available acute stroke treatment to date, but is progressively destroyed by the expansion of infarction. The underlying mechanisms of progressive infarction are not fully understood. Methods To address mechanisms, mice underwent filament occlusion of the middle cerebral artery (MCAO) for up to 4 h. Infarct development was compared between mice treated with antigen-binding fragments (Fab) against the platelet surface molecules GPIb (p0p/B Fab) or rat immunoglobulin G (IgG) Fab as control treatment. Moreover, Rag1\(^{−/−}\) mice lacking T-cells underwent the same procedures. Infarct volumes as well as the local inflammatory response were determined during vessel occlusion. Results We show that blocking of the platelet adhesion receptor, glycoprotein (GP) Ibα in mice, delays cerebral infarct progression already during occlusion and thus before recanalization/reperfusion. This therapeutic effect was accompanied by decreased T-cell infiltration, particularly at the infarct border zone, which during occlusion is supplied by collateral blood flow. Accordingly, mice lacking T-cells were likewise protected from infarct progression under occlusion. Conclusions Progressive brain infarction can be delayed by blocking detrimental lymphocyte/platelet responses already during occlusion paving the way for ultra-early treatment strategies in hyper-acute stroke before recanalization.
  • 1 to 10

DINI-Zertifikat     OPUS4 Logo

  • Contact
  • |
  • Imprint
  • |
  • Sitemap